News

Hosted on MSN4mon
Gilead’s new HIV prevention drug lenacapavir will ‘change the face of HIV,’ says CEO Daniel O’Day
Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O’Day. He dubbed lenacapavir – the ...
FiercePharma2mon
Another big payday for Daniel O’Day as Gilead boosts his compensation 5% to $23.7M
Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since he took the reins in 2019. O’Day received a compensation package of ...
pharmaphorum1d
Gilead hires Roche's pharma chief Daniel O'Day as CEO
Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO at the end of this year, the company has announced. Currently CEO of Roche Pharmaceuticals since ...